• +1-646-491-9876
    • +91-20-67278686

    Search

    Gastric Ulcers - Pipeline Review, H1 2017

    Gastric Ulcers - Pipeline Review, H1 2017

    • Report Code ID: RW0001767489
    • Category Pharmaceuticals
    • No. of Pages 42
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Gastric Ulcers - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2017, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

    Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 5 and 5 respectively.

    Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Gastric Ulcers - Overview
    Gastric Ulcers - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Gastric Ulcers - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Gastric Ulcers - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Boryung Pharmaceutical Co Ltd
    ChoDang Pharm Co Ltd
    Daewoong Pharmaceutical Co Ltd
    Kukje Pharmaceutical Industry Co Ltd
    RaQualia Pharma Inc
    XuanZhu Pharma Co Ltd
    Gastric Ulcers - Drug Profiles
    (lafutidine + irsogladine maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    anaprazole sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-6537 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGC-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cholesteryl glucoside - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWJ-1386 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWJ-206 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWP-14012 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KJ-14001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Gastric Ulcers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tegoprazan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gastric Ulcers - Dormant Projects
    Gastric Ulcers - Discontinued Products
    Gastric Ulcers - Product Development Milestones
    Featured News & Press Releases
    Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
    Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
    Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
    Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
    Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
    Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
    Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
    Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
    Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
    Oct 23, 2001: Prilosec US litigation
    May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
    May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
    Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
    Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
    Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Gastric Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Gastric Ulcers - Pipeline by Astellas Pharma Inc, H1 2017
    Gastric Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Gastric Ulcers - Pipeline by ChoDang Pharm Co Ltd, H1 2017
    Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017
    Gastric Ulcers - Pipeline by RaQualia Pharma Inc, H1 2017
    Gastric Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
    Gastric Ulcers - Dormant Projects, H1 2017
    Gastric Ulcers - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Gastric Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    Boryung Pharmaceutical Co Ltd
    ChoDang Pharm Co Ltd
    Daewoong Pharmaceutical Co Ltd
    Kukje Pharmaceutical Industry Co Ltd
    RaQualia Pharma Inc
    XuanZhu Pharma Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//gastric-ulcers-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//gastric-ulcers-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//gastric-ulcers-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments